Follow The Filings

OGN Organon & Co.

Health Care, filed as ORGANON & CO (COMMON STOCK), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 5.7%
  • $36M
  • 1 reduce

In 2026 Q2 Kahn Brothers Group trimmed Organon.

Who owns this now

Largest portfolio weights among holders, up to 5.7% (Kahn Brothers Group). Not free-float ownership.

  1. Kahn Brothers Group Reduce 5.7%

Who owns OGN

Sorted by value, long equity only, as of 2026 Q2.

History
Kahn Brothers Group 5.7%, was 5.9% Reduce −51.8% 2,670,523 $36M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by OGN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All OGN insider trades
  • $855K bought by 2 insiders
  • $553K sold by 2 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Juliana Papa Drinane Head of Mfg & Supply
    Sale
    $200K 14,761 shares at $13.57 44% of stake
    Traded Aug 5 Filed Aug 5
    ↗
  2. Lynette Holzbaur SVP and Corporate Controller
    Sale
    $353K 26,448 shares at $13.35 100% of stake
    Traded May 6 Filed May 7
    ↗
  3. Lynette Holzbaur SVP and Corporate Controller
    Buy
    $353K 26,448 shares at $13.35 +100% to stake
    Traded May 6 Filed May 7
    ↗
  4. Carrie Smith Cox Chair
    Buy
    $502K 65,400 shares at $7.67 +525% to stake
    Traded Nov 12, 2025 Filed Nov 13, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 46 share withholdings for taxes, 34 option exercises, 12 stock grants, and 1 other transaction.

Congress

2 members of Congress traded OGN in the last three years: 0 buys and 2 sales. 3 members listed it in 2025 annual reports.

All Congress trades
  1. Kevin Hern R-OK-1Joint Sell $1K–$15K Aug 5 filed Aug 12
  2. Gary C. Peters D-MI Sell $1K–$15K Jul 10, 2025 filed Nov 24, 2025

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 8.01 Filing Doc
DEFA14A Filing Doc
DEFA14A Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
DEFA14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G — Filing Doc
8-K 1.01,5.02,7.01,9.01 Filing Doc
DEFA14A Filing Doc
DEFA14A Filing Doc
DEFA14A Filing Doc
DEFA14A Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $6.26B $6.4B $6.22B
Gross profit * $3.75B $3.72B $3.31B
Gross margin * 59.8% 58.0% 53.3%
Net income $1.02B $0.864B $0.187B
Net margin * 16.3% 13.5% 3.0%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $4.51B $4.35B $4.35B
Total non-current assets * $7.55B $8.75B $8.52B
Total assets $12.06B $13.1B $12.87B
Total current liabilities $2.92B $2.72B $2.39B
Total non-current liabilities * $9.21B $9.91B $9.72B
Total equity -$70M $472M $752M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations — $939M $700M
Cash from investing — -$513M -$390M
Cash from financing — -$368M -$561M
Net change in cash -$13M -$18M -$101M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.